Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E3EO
|
|||
| Former ID |
DIB015537
|
|||
| Drug Name |
JTT-251
|
|||
| Indication | Pulmonary arterial hypertension [ICD-11: BB01.0; ICD-9: 416] | Phase 2 | [1] | |
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [2], [3] | ||
| Company |
Akros pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Pyruvate dehydrogenase kinase (PDHK) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03789643) Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension (RELIEF-PAH). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02106585) Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.